布隆妥珠单抗

化合物

布隆妥珠单抗INN:brontictuzumab;开发代号:OMP-52M51)是一种人源化单克隆抗体,设计用于治疗癌症[1][2]该药物靶向Notch1并抑制通路激活。[3]

布隆妥珠单抗
单克隆抗体
种类完整抗体
目標Notch 1
臨床資料
其他名稱OMP-52M51
ATC碼
  • 未分配
识别信息
CAS号1447814-75-6
ChemSpider
  • none
UNII
KEGG
化学信息
化学式C6392H9862N1980O1710S50
摩尔质量143,410.36 g·mol−1

该药物由OncoMed英语OncoMed开发。

参考资料

编辑
  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Brontictuzumab页面存档备份,存于互联网档案馆), American Medical Association.
  2. ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111 (PDF). WHO Drug Information. 2014, 28 (2) [2024-03-06]. (原始内容存档 (PDF)于2020-08-15). 
  3. ^ Ferrarotto, R.; Eckhardt, G.; Patnaik, A.; LoRusso, P.; Faoro, L.; Heymach, J. V.; Kapoun, A. M.; Xu, L.; Munster, P. A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors. Annals of Oncology: Official Journal of the European Society for Medical Oncology. 2018-07-01, 29 (7) [2024-03-06]. ISSN 1569-8041. PMID 29726923. doi:10.1093/annonc/mdy171. (原始内容存档于2024-05-31).